Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021
The perfusion systems market is projected to reach USD 1,198.8 million by 2021, at a CAGR of 3.9% during the forecast period 2016-2021. The growth of the market can be attributed to the increasing prevalence of cardiovascular and respiratory diseases, initiatives by governments and NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing.
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.
Research Coverage:
The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.
Research Coverage:
The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the perfusion systems market
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the perfusion systems market
- Market Development: Information about lucrative emerging markets. The report analyzes the markets for various perfusion products across regions
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the perfusion systems market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the perfusion systems market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key data from primary sources
2.2.2.2 Key insights from primary sources
2.2.2.3 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.4 MARKET DATA VALIDATION AND TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CONCLUSION
4 PREMIUM INSIGHTS
4.1 PERFUSION SYSTEMS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PERFUSION SYSTEMS MARKET, BY TYPE (2016)
4.3 CELL PERFUSION SYSTEMS MARKET, BY TYPE, 2016 VS. 2021
4.4 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases
5.2.1.2 Rising number of organ transplantations
5.2.1.2.1 Growth in aging population, increasing incidence of multiple organ failures
5.2.1.2.2 Government and NGO initiatives to encourage organ donation
5.2.1.3 Increasing investments in cell-based research
5.2.1.4 Increase in biologic manufacturing
5.2.2 RESTRAINTS
5.2.2.1 High cost of organ transplantation
5.2.2.2 Ethical concerns and high cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing pharmaceutical research in emerging markets
5.2.3.2 Rising preference for continuous manufacturing
5.2.4 CHALLENGE
5.2.4.1 Organ supply-demand gap
6 CARDIOPULMONARY PERFUSION SYSTEMS MARKET, BY COMPONENT
6.1 INTRODUCTION
6.2 OXYGENATORS
6.3 HEART-LUNG MACHINES
6.4 PERFUSION PUMPS
6.5 CANNULAS
6.6 MONITORING SYSTEMS
6.7 OTHER COMPONENTS
6.7.1 ARTERIAL FILTERS
6.7.2 RESERVOIRS
6.7.3 DATA MANAGEMENT SYSTEMS
6.7.4 CARDIOPLEGIA DELIVERY SYSTEMS
6.7.5 HEAT EXCHANGERS
6.7.6 ACCESSORIES
7 CELL PERFUSION SYSTEMS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BIOREACTOR PERFUSION SYSTEMS
7.3 MICROFLUIDIC PERFUSION SYSTEMS
7.4 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS
7.5 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS
8 EX VIVO ORGAN PERFUSION MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 HYPOTHERMIC MACHINE PERFUSION
8.3 NORMOTHERMIC MACHINE PERFUSION
9 GLOBAL PERFUSION SYSTEMS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.1.1 Rise in cardiovascular disease prevalence
9.2.1.2 Technological Advancements in Organ Preservation
9.2.1.3 Increasing Organ Transplants
9.2.1.4 Introduction of the 21st Century Cures Act
9.2.1.5 Favorable Scenario for Cell Research, Growing Research Funding
9.2.1.6 Growth of the Pharmaceutical and Biotechnology Sector
9.2.2 CANADA
9.2.2.1 Increasing incidences of heart diseases
9.2.2.2 Favorable reimbursement scenario for living donors within some provinces
9.2.2.3 Increasing investment in regenerative medicine research projects
9.3 EUROPE
9.3.1 RAPIDLY AGING POPULATION, HIGH PREVALENCE OF CARDIOVASCULAR DISEASES IN EUROPE
9.3.2 EUROPE-5
9.3.2.1 Changes in organ donation laws in Wales
9.3.2.2 Strong academic and research base in Germany
9.3.2.3 Funding for research in the U.K.
9.3.2.4 Increasing cancer research in France
9.3.2.5 Italy: Growing biotech industry to aid market growth
9.3.3 ROE
9.3.3.1 Strong presence of pharmaceutical and biotechnology companies
9.3.3.2 Increasing research in Denmark and Sweden
9.4 ASIA-PACIFIC
9.4.1 INCREASING AGING POPULATION, RISE IN CARDIOVASCULAR SURGERY
9.4.2 JAPAN
9.4.2.1 Rising organ donations and transplants
9.4.2.2 Rise in vaccine production in Japan
9.4.2.3 Regenerative medicine and biomedical & medical research in Japan
9.4.3 CHINA
9.4.3.1 Regulatory framework for voluntary organ donations
9.4.3.2 Increasing government interest in biomedical and biotechnology industries
9.4.3.3 Growth of the pharmaceutical and biotechnology R&D industry and CROs sector
9.4.4 INDIA
9.4.4.1 Religious beliefs and lack of healthcare infrastructure in India
9.4.4.2 Growing pharmaceutical and biotechnology industry, government initiatives
9.4.5 REST OF ASIA-PACIFIC
9.4.5.1 Taiwan: Increasing government support for academic and commercial R&D
9.4.5.2 Establishment of R&D centers in Singapore
9.4.5.3 Korea-U.S. free trade agreement (KORUS)
9.5 REST OF THE WORLD
9.5.1.1 Campaigns to encourage organ donation in Brazil
9.5.1.2 Flourishing biotechnology and pharmaceutical markets in Brazil
9.5.1.3 Significant developments in the pharmaceutical market in Africa
9.5.1.4 Favorable regulatory environment in Saudi Arabia, Iran, and Israel
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.1.1 VANGUARDS
10.1.2 INNOVATOR
10.1.3 DYNAMIC
10.1.4 EMERGING
10.2 COMPETITIVE BENCHMARKING
10.2.1 PRODUCT OFFERINGS
10.2.2 BUSINESS STRATEGY
*Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).
11 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 GETINGE AB
11.2 MEDTRONIC PLC
11.3 LIVANOVA PLC
11.4 TERUMO CORPORATION
11.5 NIPRO CORPORATION
11.6 XENIOS AG (ACQUIRED BY FRESENIUS MEDICAL CARE AG & CO. KGAA)
11.7 REPLIGEN CORPORATION
11.8 SPECTRUM LABORATORIES, INC.
11.9 MERCK KGAA
11.10 HARVARD BIOSCIENCE, INC.
11.11 ALA SCIENTIFIC INSTRUMENTS, INC.
11.12 LIFELINE SCIENTIFIC, INC. (ORGAN RECOVERY SYSTEMS, INC.)
11.13 XVIVO PERFUSION AB
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.3.1 FEATURES AND BENEFITS OF RT:
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key data from primary sources
2.2.2.2 Key insights from primary sources
2.2.2.3 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.4 MARKET DATA VALIDATION AND TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CONCLUSION
4 PREMIUM INSIGHTS
4.1 PERFUSION SYSTEMS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PERFUSION SYSTEMS MARKET, BY TYPE (2016)
4.3 CELL PERFUSION SYSTEMS MARKET, BY TYPE, 2016 VS. 2021
4.4 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases
5.2.1.2 Rising number of organ transplantations
5.2.1.2.1 Growth in aging population, increasing incidence of multiple organ failures
5.2.1.2.2 Government and NGO initiatives to encourage organ donation
5.2.1.3 Increasing investments in cell-based research
5.2.1.4 Increase in biologic manufacturing
5.2.2 RESTRAINTS
5.2.2.1 High cost of organ transplantation
5.2.2.2 Ethical concerns and high cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing pharmaceutical research in emerging markets
5.2.3.2 Rising preference for continuous manufacturing
5.2.4 CHALLENGE
5.2.4.1 Organ supply-demand gap
6 CARDIOPULMONARY PERFUSION SYSTEMS MARKET, BY COMPONENT
6.1 INTRODUCTION
6.2 OXYGENATORS
6.3 HEART-LUNG MACHINES
6.4 PERFUSION PUMPS
6.5 CANNULAS
6.6 MONITORING SYSTEMS
6.7 OTHER COMPONENTS
6.7.1 ARTERIAL FILTERS
6.7.2 RESERVOIRS
6.7.3 DATA MANAGEMENT SYSTEMS
6.7.4 CARDIOPLEGIA DELIVERY SYSTEMS
6.7.5 HEAT EXCHANGERS
6.7.6 ACCESSORIES
7 CELL PERFUSION SYSTEMS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BIOREACTOR PERFUSION SYSTEMS
7.3 MICROFLUIDIC PERFUSION SYSTEMS
7.4 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS
7.5 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS
8 EX VIVO ORGAN PERFUSION MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 HYPOTHERMIC MACHINE PERFUSION
8.3 NORMOTHERMIC MACHINE PERFUSION
9 GLOBAL PERFUSION SYSTEMS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.1.1 Rise in cardiovascular disease prevalence
9.2.1.2 Technological Advancements in Organ Preservation
9.2.1.3 Increasing Organ Transplants
9.2.1.4 Introduction of the 21st Century Cures Act
9.2.1.5 Favorable Scenario for Cell Research, Growing Research Funding
9.2.1.6 Growth of the Pharmaceutical and Biotechnology Sector
9.2.2 CANADA
9.2.2.1 Increasing incidences of heart diseases
9.2.2.2 Favorable reimbursement scenario for living donors within some provinces
9.2.2.3 Increasing investment in regenerative medicine research projects
9.3 EUROPE
9.3.1 RAPIDLY AGING POPULATION, HIGH PREVALENCE OF CARDIOVASCULAR DISEASES IN EUROPE
9.3.2 EUROPE-5
9.3.2.1 Changes in organ donation laws in Wales
9.3.2.2 Strong academic and research base in Germany
9.3.2.3 Funding for research in the U.K.
9.3.2.4 Increasing cancer research in France
9.3.2.5 Italy: Growing biotech industry to aid market growth
9.3.3 ROE
9.3.3.1 Strong presence of pharmaceutical and biotechnology companies
9.3.3.2 Increasing research in Denmark and Sweden
9.4 ASIA-PACIFIC
9.4.1 INCREASING AGING POPULATION, RISE IN CARDIOVASCULAR SURGERY
9.4.2 JAPAN
9.4.2.1 Rising organ donations and transplants
9.4.2.2 Rise in vaccine production in Japan
9.4.2.3 Regenerative medicine and biomedical & medical research in Japan
9.4.3 CHINA
9.4.3.1 Regulatory framework for voluntary organ donations
9.4.3.2 Increasing government interest in biomedical and biotechnology industries
9.4.3.3 Growth of the pharmaceutical and biotechnology R&D industry and CROs sector
9.4.4 INDIA
9.4.4.1 Religious beliefs and lack of healthcare infrastructure in India
9.4.4.2 Growing pharmaceutical and biotechnology industry, government initiatives
9.4.5 REST OF ASIA-PACIFIC
9.4.5.1 Taiwan: Increasing government support for academic and commercial R&D
9.4.5.2 Establishment of R&D centers in Singapore
9.4.5.3 Korea-U.S. free trade agreement (KORUS)
9.5 REST OF THE WORLD
9.5.1.1 Campaigns to encourage organ donation in Brazil
9.5.1.2 Flourishing biotechnology and pharmaceutical markets in Brazil
9.5.1.3 Significant developments in the pharmaceutical market in Africa
9.5.1.4 Favorable regulatory environment in Saudi Arabia, Iran, and Israel
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.1.1 VANGUARDS
10.1.2 INNOVATOR
10.1.3 DYNAMIC
10.1.4 EMERGING
10.2 COMPETITIVE BENCHMARKING
10.2.1 PRODUCT OFFERINGS
10.2.2 BUSINESS STRATEGY
*Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).
11 COMPANY PROFILE
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 GETINGE AB
11.2 MEDTRONIC PLC
11.3 LIVANOVA PLC
11.4 TERUMO CORPORATION
11.5 NIPRO CORPORATION
11.6 XENIOS AG (ACQUIRED BY FRESENIUS MEDICAL CARE AG & CO. KGAA)
11.7 REPLIGEN CORPORATION
11.8 SPECTRUM LABORATORIES, INC.
11.9 MERCK KGAA
11.10 HARVARD BIOSCIENCE, INC.
11.11 ALA SCIENTIFIC INSTRUMENTS, INC.
11.12 LIFELINE SCIENTIFIC, INC. (ORGAN RECOVERY SYSTEMS, INC.)
11.13 XVIVO PERFUSION AB
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.3.1 FEATURES AND BENEFITS OF RT:
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
LIST OF TABLES
Table 1 BIOMANUFACTURING PROJECTS ANNOUNCED IN 2015 AND 2016
Table 2 CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 3 OXYGENATORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 4 HEART-LUNG MACHINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 5 PERFUSION PUMPS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 6 CANNULAS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 7 MONITORING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 8 OTHER COMPONENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 9 CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 10 BIOREACTOR PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 11 MICROFLUIDIC PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 12 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 13 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 14 EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 15 ADVANTAGES AND DISADVANTAGES OF THE HMP TECHNIQUE
Table 16 HYPOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 17 NORMOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 18 GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 19 GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 20 NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 21 NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 22 NORTH AMERICA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 23 NORTH AMERICA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 24 NORTH AMERICA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 25 NUMBER OF ORGAN TRANSPLANTS IN THE U.S. (2014-2016)
Table 26 U.S.: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 27 U.S.: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 28 U.S.: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 29 U.S.: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 30 CANADA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 31 CANADA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 32 CANADA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 33 CANADA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 34 EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 35 EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 36 EUROPE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 37 EUROPE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 38 EUROPE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 39 EUROPE-5: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 40 EUROPE-5: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 41 EUROPE-5: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 42 EUROPE-5: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 43 INDICATIVE LIST: COMPANIES HEADQUARTERED IN ROE COUNTRIES
Table 44 ROE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 45 ROE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 46 ROE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 47 ROE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 48 ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 49 ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 50 ASIA-PACIFIC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 51 ASIA-PACIFIC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 52 ASIA-PACIFIC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 53 NUMBER OF ORGAN DONATIONS AND TRANSPLANTS IN JAPAN (2013-2016)
Table 54 JAPAN: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 55 JAPAN: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 56 JAPAN: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 57 JAPAN: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 58 CHINA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 59 CHINA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 60 CHINA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 61 CHINA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 62 INDIA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 63 INDIA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 64 INDIA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 65 INDIA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 66 ROAPAC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 67 ROAPAC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 68 ROAPAC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 69 ROAPAC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 70 NUMBER OF ORGAN DONATIONS (2008 VS. 2015)
Table 71 ROW: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 72 ROW: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 73 ROW: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 74 ROW: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 1 BIOMANUFACTURING PROJECTS ANNOUNCED IN 2015 AND 2016
Table 2 CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 3 OXYGENATORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 4 HEART-LUNG MACHINES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 5 PERFUSION PUMPS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 6 CANNULAS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 7 MONITORING SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 8 OTHER COMPONENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 9 CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 10 BIOREACTOR PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 11 MICROFLUIDIC PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 12 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 13 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 14 EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 15 ADVANTAGES AND DISADVANTAGES OF THE HMP TECHNIQUE
Table 16 HYPOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 17 NORMOTHERMIC MACHINE PERFUSION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 18 GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 19 GLOBAL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 20 NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 21 NORTH AMERICA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 22 NORTH AMERICA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 23 NORTH AMERICA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 24 NORTH AMERICA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 25 NUMBER OF ORGAN TRANSPLANTS IN THE U.S. (2014-2016)
Table 26 U.S.: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 27 U.S.: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 28 U.S.: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 29 U.S.: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 30 CANADA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 31 CANADA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 32 CANADA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 33 CANADA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 34 EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
Table 35 EUROPE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 36 EUROPE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 37 EUROPE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 38 EUROPE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 39 EUROPE-5: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 40 EUROPE-5: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 41 EUROPE-5: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 42 EUROPE-5: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 43 INDICATIVE LIST: COMPANIES HEADQUARTERED IN ROE COUNTRIES
Table 44 ROE: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 45 ROE: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 46 ROE: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 47 ROE: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 48 ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
Table 49 ASIA-PACIFIC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 50 ASIA-PACIFIC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 51 ASIA-PACIFIC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 52 ASIA-PACIFIC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 53 NUMBER OF ORGAN DONATIONS AND TRANSPLANTS IN JAPAN (2013-2016)
Table 54 JAPAN: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 55 JAPAN: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 56 JAPAN: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 57 JAPAN: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 58 CHINA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 59 CHINA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 60 CHINA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 61 CHINA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 62 INDIA: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 63 INDIA: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 64 INDIA: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 65 INDIA: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 66 ROAPAC: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 67 ROAPAC: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 68 ROAPAC: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 69 ROAPAC: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
Table 70 NUMBER OF ORGAN DONATIONS (2008 VS. 2015)
Table 71 ROW: PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 72 ROW: CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2014-2021 (USD MILLION)
Table 73 ROW: CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 74 ROW: EX VIVO ORGAN PERFUSION MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
LIST OF FIGURES
Figure 1 PERFUSION SYSTEMS MARKET SEGMENTATION
Figure 2 PERFUSION SYSTEMS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 SAMPLING FRAME: PRIMARY RESEARCH
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 RESEARCH DESIGN
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 PERFUSION SYSTEMS MARKET, BY TYPE: CARDIOPULMONARY PERFUSION SYSTEMS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
Figure 10 CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2016 VS. 2021
Figure 11 EX VIVO ORGAN PERFUSION MARKET SIZE (USD MILLION), BY TECHNIQUE, 2016 VS. 2021
Figure 12 CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2016 VS. 2021
Figure 13 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET
Figure 14 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE PERFUSION SYSTEMS MARKET IN 2016
Figure 15 CARDIOPULMONARY PERFUSION SEGMENT DOMINATED THE PERFUSION SYSTEMS MARKET IN 2016
Figure 16 BIOREACTOR PERFUSION SYSTEMS WILL CONTINUE TO DOMINATE THE CELL PERFUSION SYSTEMS MARKET IN 2021
Figure 17 NORTH AMERICA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 18 GLOBAL PERFUSION SYSTEMS MARKET SHARE, BY REGION (2016–2021)
Figure 19 NORTH AMERICA: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 20 NIH SPENDING ON STEM CELL RESEARCH, 2013-2016 (USD BILLION)
Figure 21 NUMBER OF NEW BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2014-2016
Figure 22 EUROPE: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 23 APAC: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 24 ROW: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 25 DIVE CHART
Figure 26 GETINGE AB: COMPANY SNAPSHOT (2016)
Figure 27 GETINGE AB: PRODUCT OFFERING SCORECARD
Figure 28 GETINGE AB: BUSINESS STRATEGY SCORECARD
Figure 29 MEDTRONIC PLC: COMPANY SNAPSHOT (2016)
Figure 30 MEDTRONIC PLC: PRODUCT OFFERING SCORECARD
Figure 31 MEDTRONIC PLC: BUSINESS STRATEGY SCORECARD
Figure 32 LIVANOVA PLC: COMPANY SNAPSHOT (2015)
Figure 33 LIVANOVA PLC: PRODUCT OFFERING SCORECARD
Figure 34 LIVANOVA PLC: BUSINESS STRATEGY SCORECARD
Figure 35 TERUMO CORPORATION: COMPANY SNAPSHOT (2015)
Figure 36 TERUMO CORPORATION: PRODUCT OFFERING SCORECARD
Figure 37 TERUMO CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 38 NIPRO CORPORATION: COMPANY SNAPSHOT (2015)
Figure 39 NIPRO CORPORATION: PRODUCT OFFERING SCORECARD
Figure 40 NIPRO CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 41 XENIOS AG: PRODUCT OFFERING SCORECARD
Figure 42 XENIOS AG: BUSINESS STRATEGY SCORECARD
Figure 43 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2015)
Figure 44 REPLIGEN CORPORATION: PRODUCT OFFERING SCORECARD
Figure 45 REPLIGEN CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 46 SPECTRUM LABORATORIES, INC.: PRODUCT OFFERING SCORECARD
Figure 47 SPECTRUM LABORATORIES, INC.: BUSINESS STRATEGY SCORECARD
Figure 48 MERCK KGAA: COMPANY SNAPSHOT (2015)
Figure 49 MERCK KGAA: PRODUCT OFFERING SCORECARD
Figure 50 MERCK KGAA: BUSINESS STRATEGY SCORECARD
Figure 51 HARVARD BIOSCIENCE, INC.: COMPANY SNAPSHOT (2015)
Figure 52 HARVARD BIOSCIENCE, INC.: PRODUCT OFFERING SCORECARD
Figure 53 HARVARD BIOSCIENCE, INC.: BUSINESS STRATEGY SCORECARD
Figure 54 ALA SCIENTIFIC INSTRUMENTS, INC.: PRODUCT OFFERING SCORECARD
Figure 55 ALA SCIENTIFIC INSTRUMENTS, INC.: BUSINESS STRATEGY SCORECARD
Figure 56 LIFELINE SCIENTIFIC, INC.: COMPANY SNAPSHOT (2015)
Figure 57 LIFELINE SCIENTIFIC, INC.: PRODUCT OFFERING SCORECARD
Figure 58 LIFELINE SCIENTIFIC, INC.: BUSINESS STRATEGY SCORECARD
Figure 59 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2015)
Figure 60 XVIVO PERFUSION AB: PRODUCT OFFERING SCORECARD
Figure 61 XVIVO PERFUSION AB: BUSINESS STRATEGY SCORECARD
Figure 1 PERFUSION SYSTEMS MARKET SEGMENTATION
Figure 2 PERFUSION SYSTEMS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 SAMPLING FRAME: PRIMARY RESEARCH
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 RESEARCH DESIGN
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 PERFUSION SYSTEMS MARKET, BY TYPE: CARDIOPULMONARY PERFUSION SYSTEMS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
Figure 10 CARDIOPULMONARY PERFUSION SYSTEMS MARKET SIZE, BY COMPONENT, 2016 VS. 2021
Figure 11 EX VIVO ORGAN PERFUSION MARKET SIZE (USD MILLION), BY TECHNIQUE, 2016 VS. 2021
Figure 12 CELL PERFUSION SYSTEMS MARKET SIZE, BY TYPE, 2016 VS. 2021
Figure 13 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET
Figure 14 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE PERFUSION SYSTEMS MARKET IN 2016
Figure 15 CARDIOPULMONARY PERFUSION SEGMENT DOMINATED THE PERFUSION SYSTEMS MARKET IN 2016
Figure 16 BIOREACTOR PERFUSION SYSTEMS WILL CONTINUE TO DOMINATE THE CELL PERFUSION SYSTEMS MARKET IN 2021
Figure 17 NORTH AMERICA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 18 GLOBAL PERFUSION SYSTEMS MARKET SHARE, BY REGION (2016–2021)
Figure 19 NORTH AMERICA: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 20 NIH SPENDING ON STEM CELL RESEARCH, 2013-2016 (USD BILLION)
Figure 21 NUMBER OF NEW BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2014-2016
Figure 22 EUROPE: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 23 APAC: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 24 ROW: PERFUSION SYSTEMS MARKET SNAPSHOT
Figure 25 DIVE CHART
Figure 26 GETINGE AB: COMPANY SNAPSHOT (2016)
Figure 27 GETINGE AB: PRODUCT OFFERING SCORECARD
Figure 28 GETINGE AB: BUSINESS STRATEGY SCORECARD
Figure 29 MEDTRONIC PLC: COMPANY SNAPSHOT (2016)
Figure 30 MEDTRONIC PLC: PRODUCT OFFERING SCORECARD
Figure 31 MEDTRONIC PLC: BUSINESS STRATEGY SCORECARD
Figure 32 LIVANOVA PLC: COMPANY SNAPSHOT (2015)
Figure 33 LIVANOVA PLC: PRODUCT OFFERING SCORECARD
Figure 34 LIVANOVA PLC: BUSINESS STRATEGY SCORECARD
Figure 35 TERUMO CORPORATION: COMPANY SNAPSHOT (2015)
Figure 36 TERUMO CORPORATION: PRODUCT OFFERING SCORECARD
Figure 37 TERUMO CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 38 NIPRO CORPORATION: COMPANY SNAPSHOT (2015)
Figure 39 NIPRO CORPORATION: PRODUCT OFFERING SCORECARD
Figure 40 NIPRO CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 41 XENIOS AG: PRODUCT OFFERING SCORECARD
Figure 42 XENIOS AG: BUSINESS STRATEGY SCORECARD
Figure 43 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2015)
Figure 44 REPLIGEN CORPORATION: PRODUCT OFFERING SCORECARD
Figure 45 REPLIGEN CORPORATION: BUSINESS STRATEGY SCORECARD
Figure 46 SPECTRUM LABORATORIES, INC.: PRODUCT OFFERING SCORECARD
Figure 47 SPECTRUM LABORATORIES, INC.: BUSINESS STRATEGY SCORECARD
Figure 48 MERCK KGAA: COMPANY SNAPSHOT (2015)
Figure 49 MERCK KGAA: PRODUCT OFFERING SCORECARD
Figure 50 MERCK KGAA: BUSINESS STRATEGY SCORECARD
Figure 51 HARVARD BIOSCIENCE, INC.: COMPANY SNAPSHOT (2015)
Figure 52 HARVARD BIOSCIENCE, INC.: PRODUCT OFFERING SCORECARD
Figure 53 HARVARD BIOSCIENCE, INC.: BUSINESS STRATEGY SCORECARD
Figure 54 ALA SCIENTIFIC INSTRUMENTS, INC.: PRODUCT OFFERING SCORECARD
Figure 55 ALA SCIENTIFIC INSTRUMENTS, INC.: BUSINESS STRATEGY SCORECARD
Figure 56 LIFELINE SCIENTIFIC, INC.: COMPANY SNAPSHOT (2015)
Figure 57 LIFELINE SCIENTIFIC, INC.: PRODUCT OFFERING SCORECARD
Figure 58 LIFELINE SCIENTIFIC, INC.: BUSINESS STRATEGY SCORECARD
Figure 59 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2015)
Figure 60 XVIVO PERFUSION AB: PRODUCT OFFERING SCORECARD
Figure 61 XVIVO PERFUSION AB: BUSINESS STRATEGY SCORECARD
